Axcelon leverages bacterial cellulose expertise with Nanoderm launch
May 5, 2015
Axcelon Biopolymers Corp. (ABC) announced today that it is contemplating building its demonstration bacterial nanocellulose (BNC) production facility in St. Félicien, Qc.
February 21, 2017

AXCELON ANNOUNCES ISSUANCE OF A MAJOR US PATENT FOR BIOMEDICAL APPLICATIONS OF BACTERIAL CELLULOSE COMPOSITE

London, Ontario, November 19th, 2015. Axcelon Biopolymers Corp. (ABC) announced today that the US Patent Office (USPTO) has issued Patent No.US 9,186,436 entitled “Poly(Vinyl Alcohol)-Bacterial Cellulose Nanocomposite”, a composition of matter patent, to Axcelon. Among the nineteen claims are those for use of the composite in a variety of medical applications including vascular grafts, catheter covering dressings, dialysis membranes, stent coatings and dental implants.

“We are delighted by the issuance of this important patent, which together with the process patent (US 8,551,502) issued earlier and with 37 claims, represents a strong IP position for Axcelon in the bacterial cellulose composites arena”, said Dr. Chandra Panchal, CEO of Axcelon. “Research in our laboratories has shown that the anisotropic PVA-BC composites have ideal characteristics to be potentially used as small diameter vascular grafts for by-pass operations, such as coronary by-pass operations, for which there are no off-the shelf grafts available currently”, he added.

In addition to the PVA-BC patents, Axcelon also has proprietary positions in other composites, such as PolyHEMA-BC Transparent Nanocomposites (US 8,940,337) for optical applications as well as for Biocompatible Polyamic acid (US 8,956,638) for utility in imparting biocompatibility to biomedical conduits, including vascular grafts.

Axcelon, through its majority owned subsidiary Axcelon Dermacare Inc., currently markets an innovative wound dressing, NANODERM™.  NANODERM™ is a unique bacterial nanocellulose product indicated for a variety of wound treatments including burns, dermabrasions as well as acute and chronic wounds. In most cases, it is a one-time dressing application as the product provides a suitable barrier to infections while allowing gaseous exchange, exudate evaporation, and pain alleviation. NANODERM™, has been registered with Health Canada as a Class II medical device, and is manufactured under license from ADI by ZBX Corporation of Toronto under ISO 13485 QMS.  It is distributed in Canada through The Stevens Company.

 

About Axcelon Biopolymers Corp.

Axcelon is a privately held company developing bacterial cellulose based products for biomedical devices as well as for non-medical applications. The company has several proprietary assets for development of advanced wound care products, cardiovascular grafts, tympanic membrane as well as other high value consumer products. In November 2014, the company announced establishment and financing of its wound care subsidiary Axcelon Dermacare Inc. With head office in London, Ontario, the company has activities in Toronto as well as Montreal, Quebec.

 

Contact:    Dr.Chandra Panchal, Chairman & CEO

cpanchal@axcelonbp.com

 

Leave a Reply

Your email address will not be published. Required fields are marked *